Our in vivo findings in a mouse model of PNET also substantiate that combination therapy of PD-1 inhibitor and vorinostat may be more effective in controlling tumor growth than either monotherapy. This evidence concerns the gene PDCD1 and primitive neuroectodermal tumor.